Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rocuronium bolus maintenance · 1 trial · 1 indication
Total dose from administration of intubating dose to reappearance of T3 (the third twitch of a Train of Four \[TOF\] stimulation) after the last maintenance bolus dose or discontinuation of Zemuron (rocuronium) infusion (Per protocol \[PP\] data set)
| Arm | Type | Description |
|---|---|---|
| Rocuronium bolus maintenance | EXPERIMENTAL | Rocuronium bolus maintenance |
| Rocuronium continuous infusion maintenance | EXPERIMENTAL | Rocuronium continuous infusion maintenance |
| Name | Type | Description |
|---|---|---|
| Rocuronium bolus maintenance | DRUG | Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation |
| rocuronium continuous infusion maintenance | DRUG | Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation |
Inclusion Criteria: * Male and female subjects from birth up to 17 years of age who are scheduled for surgery with an anticipated duration of anesthesia of about 2 hours or more requiring a maintenance muscle relaxation dose(s). Exclusion Criteria: * Subjects whose parent(s) or legal guardian(s) ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan, Astra-Zeneca |
| Cardinal Health, Inc. | CAH | 1 | - | Undisclosed |
| Medtronic Plc | MDT | 1 | N/A | Undisclosed |
Rocuronium bolus maintenance is used for anesthesia. It is a small molecule being studied as a maintenance dose of rocuronium during anesthesia. The drug is being developed by Merck & Company, Inc. for use in the therapeutic area of pain, specifically in the context of anesthesia.
Rocuronium bolus maintenance is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this drug for use in anesthesia. The drug is a small molecule and is currently in Phase 3 clinical development.
Rocuronium bolus maintenance is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for use in anesthesia, with one completed Phase 3 trial involving 149 participants.
Rocuronium bolus maintenance has one completed clinical trial, NCT00124735, titled 'A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)'. This Phase 3 trial enrolled 149 participants and was a controlled, randomized study in anesthesia.
Rocuronium bolus maintenance is related to Zemuron, as the clinical trial NCT00124735 refers to rocuronium bromide (Zemuron®). The drug is being studied as a maintenance dose of rocuronium, which is the active ingredient in Zemuron. The trial focused on determining dose requirements in pediatric and adolescent subjects.